NANCY DENYES - 05 Feb 2024 Form 4 Insider Report for aTYR PHARMA INC (LIFE)

Role
General Counsel
Signature
/s/ Nancy E. Denyes
Issuer symbol
LIFE
Transactions as of
05 Feb 2024
Transactions value $
$0
Form type
4
Filing time
06 Feb 2024, 20:15:45 UTC
Previous filing
09 Jan 2024
Next filing
06 Jun 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LIFE Common stock Options Exercise +2,688 +22% 14,767 05 Feb 2024 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LIFE Restricted Stock Unit Options Exercise $0 -2,688 -33% $0 5,374 05 Feb 2024 Common Stock 2,688 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares acquired upon the vesting of restricted stock units (RSUs) granted to the Reporting Person on February 3, 2022.
F2 Restricted stock units convert into common stock on a one-for-one basis.
F3 The RSUs vest in four equal annual installments beginning on February 3, 2023, such that the RSUs will fully vest on February 3, 2026. The RSUs are subject to accelerated vesting upon termination without cause upon a change of control of the Issuer.